Travecta Therapeutics, an emerging biotech company utilizing its novel Blood-Brain Barrier (BBB) Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system (CNS), presented its corporate strategy at the second annual TKS 1 Investor Day in Singapore. The Investor Day was attended by current and potential investors in the TKS 1 fund, including venture capitalists, strategic investors, family offices, and leaders from the biotech and pharmaceutical industry.

“Travecta had a phenomenal year in 2018, accomplishing all the milestones we had set for the company, so the conference was an excellent opportunity to showcase our potential to investors,” said Douglas Hicks, Chief Business Officer of Travecta. “We are building on our recent success as we raise our Series A funding for the execution of our strategic plan to advance our internal pipeline into the clinic and move one step closer to eliminating the immense gap between therapeutic need and effective treatment in CNS disorders.”

Travecta also enters into partnerships with pharmaceutical companies, providing companies access to the Travecta Platform for the targeted delivery of their therapeutic agents across the BBB. Travecta’s process allows partners to rapidly confirm BBB transport through feasibility studies that generate in vitro and in vivo transport data of their molecule generated with Travecta’s proprietary models.

SPRIM Ventures and Tikehau Capital (TKO.FP) hosted the Investor Day event on behalf of their venture capital fund TKS 1. TKS 1 provides early-stage capital to innovative companies offering solutions that move science forward in the health sector. Travecta was seeded by TKS 1 in 2017.

Tikehau Capital is an alternative asset management and investment group with €15.9 billion of assets under management (as of 30 September 2018) and shareholders’ equity of €2.3 billion (as of 30 June 2018). The group invests in various asset classes (private debt, real estate, private equity and liquid strategies), including through its asset management subsidiary Tikehau IM, on behalf of institutional and private investors. Controlled by its managers, alongside leading institutional partners, Tikehau Capital employs 260 staff (as of 30 September 2018) in its Paris, London, Brussels, Madrid, Milan, New York, Seoul and Singapore offices.

SPRIM Ventures is the venture arm of SPRIM, a life-science consulting agency for the full lifecycle of a product. Multi-nationals, startups, institutions and governments around the world turn to SPRIM for expertise in developing relevant, fresh and meaningful health innovations. From traditional categories like nutrition, cosmetics, personal care, prescription and medical devices, to the new health frontier of digital-connected devices and algorithm-based diagnostics, SPRIM brings together game-changing science and winning commercial results.

About Travecta Therapeutics

Travecta Therapeutics is an emerging biotech company developing a platform that leverages proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents to the brain and eye. Travecta’s platform and know-how allows identification and categorization of small molecules for enabling their transport across the blood-brain barrier (BBB) and blood-retina barrier (BRB). Travecta partners with pharmaceutical companies to apply the platform and assist them in overcoming the challenges associated with delivering drugs across the BBB and BRB. Travecta’s internal program focuses on the development of molecules that treat diseases of the central nervous system and the eye.
Travecta Therapeutics was founded by experienced scientific leaders from Duke-NUS and backed by TKS1, a life science-focused venture capital fund formed by the partnership between SPRIM and Tikehau Capital. Travecta has offices in Philadelphia and Singapore.

PHILADELPHIA – February 7, 2019